ZS Pharma's PhIII ZS-9 results positive, but raise safety concerns
This article was originally published in Scrip
Executive Summary
Detailed results from ZS Pharma's Phase III study of ZS-9 (sodium zirconium cyclosilicate), the Texas company's hyperkalemia drug, have confirmed that the drug works, but there are concerns about the drug's long-term safety.